Concurrent Chemoradiation with Low-Dose Weekly Cisplatin in Locally Advanced Stage IV Head and Neck Squamous Cell Carcinoma
Myoung Hee Kang, Jung Hun Kang, Haa-Na Song, Bae Kwon Jeong, Gyu Young Chai, Kimun Kang, Seung Hoon Woo, Jung Je Park, Jin Pyeong Kim
Cancer Res Treat. 2015;47(3):441-447. Published online 2014 Dec 2 DOI: https://doi.org/10.4143/crt.2013.219
Citations to this article as recorded by 
Transcriptomic analysis reveals differential adaptation of colorectal cancer cells to low and acute doses of cisplatin
Heena Saini, Rakshita Dave, Subhashree Chatterjee, Ayushi Mandloi, Harshita Sharma, Ankita Daiya, Sudeshna Mukherjee, Rajdeep Chowdhury, Shibasish Chowdhury
Gene.2023; 864: 147304. CrossRef
A Study Comparing Acute Toxicities of Cetuximab and Cisplatin in Patients Undergoing Definitive Chemoradiation With Intensity-Modulated Radiotherapy for Locally Advanced Carcinoma Head and Neck
Shruthi Venkateshulu, Kiran Kumar BR
Cureus.2021;[Epub] CrossRef
Comparative study on hemato- and nephrotoxicity profile of weekly versus every 3-weekly cisplatin dosage during induction chemotherapy in locally advanced head neck squamous cell carcinoma
Adity Chakraborty, Abhinandan Bhattacharjee, Amlan Jyoti Nath, Shibashis Deb, Aakanksha Rathor
The Egyptian Journal of Otolaryngology.2021;[Epub] CrossRef
Mitochondrial Superoxide Dismutase in Cisplatin-Induced Kidney Injury
Kranti A. Mapuskar, Emily J. Steinbach, Amira Zaher, Dennis P. Riley, Robert A. Beardsley, Jeffery L. Keene, Jon T. Holmlund, Carryn M. Anderson, Diana Zepeda-Orozco, John M. Buatti, Douglas R. Spitz, Bryan G. Allen
Antioxidants.2021; 10(9): 1329. CrossRef
Treatment strategy and outcomes in locally advanced head and neck squamous cell carcinoma: a nationwide retrospective cohort study (KCSG HN13–01)
Yun-Gyoo Lee, Eun Joo Kang, Bhumsuk Keam, Jin-Hyuk Choi, Jin-Soo Kim, Keon Uk Park, Kyoung Eun Lee, Jung Hye Kwon, Keun-Wook Lee, Min Kyoung Kim, Hee Kyung Ahn, Seong Hoon Shin, Hye Ryun Kim, Sung-Bae Kim, Hwan Jung Yun
BMC Cancer.2020;[Epub] CrossRef
Prognostic Value of Combined Programmed Cell Death 1 Ligand and p16 Expression Predicting Responsiveness to Radiotherapy in Patients with Oropharyngeal Squamous Cell Carcinoma
Minsu Kwon, Dae Hwan Kim, Ki Ju Cho, Youngchul Kim, Jin Pyeong Kim, Bae Kwon Jeong, Jong Sil Lee, Ji-Hyun Seo, Jung Je Park
Korean Journal of Otorhinolaryngology-Head and Neck Surgery.2019; 62(12): 712. CrossRef
Topical issues of chemoradiotherapy for oropharyngeal squamous cell carcinoma: the efficiency and toxicity of chemotherapy regimens with the goal of radiomodification
A. I. Stukan, R. A. Murashko, V. N. Bodnya, Yu. M. Makarova, I. N. Vasilenko
Onkologiya. Zhurnal imeni P.A.Gertsena.2018; 7(3): 61. CrossRef
Persistent Head and Neck Cancer Following First-Line Treatment
Teresa Steinbichler, Madeleine Lichtenecker, Maria Anegg, Daniel Dejaco, Barbara Kofler, Volker Schartinger, Maria-Therese Kasseroler, Britta Forthuber, Andrea Posch, Herbert Riechelmann
Cancers.2018; 10(11): 421. CrossRef
Management of locally advanced HPV-related oropharyngeal squamous cell carcinoma: where are we?
Stuart E. Samuels, Avraham Eisbruch, Jonathan J. Beitler, June Corry, Carol R. Bradford, Nabil F. Saba, Michiel W. M. van den Brekel, Robert Smee, Primož Strojan, Carlos Suárez, William M. Mendenhall, Robert P. Takes, Juan P. Rodrigo, Missak Haigentz, Ale
European Archives of Oto-Rhino-Laryngology.2016; 273(10): 2877. CrossRef